Markulan, L., & Makarevych, L. (2022). Pembrolizumab as an immunotherapy drug in the treatment of a patient with recurrent (unresectable) cancer of the lower lip. General Surgery, (2), 75–82. https://doi.org/10.30978/GS-2022-2-75